Danaher stock: CEO sets 2027 growth base at 4% to 5%

Published on 11/10/2026 at 15:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Danaher stock enters a new phase under CEO Julie Sawyer Montgomery. She is emphasizing commercial execution, innovation, talent and disciplined capital allocation.

Growth levers and investor watchpoints

CEO Julie Sawyer Montgomery is prioritizing commercial execution, innovation, talent and capital allocation.
AI drug discovery, diagnostics, Cytiva and China are central to Danaher's medium-term growth case.
Reshoring revenue is expected to become more visible from 2028 onward.

Danaher Corp., US2358511028, Illustration mit AI erstellt.

Danaher is setting a new growth agenda after CEO Julie Sawyer Montgomery used the UBS Global Healthcare Conference on Monday, November 9, to outline a path toward faster expansion. Management sees 4% to 5% core growth excluding respiratory as the starting point for 2027, with stronger execution and market-share gains supporting a longer-term move toward high-single-digit growth.

Danaher stock traded at 208.20 euros on Lang & Schwarz at 15:35 CET on Tuesday, November 10, 2026.

Investing.com reported that Montgomery identified commercial execution, innovation, talent and capital allocation as the main levers. Danaher wants to increase cross-selling between operating companies and apply its Danaher Business System more consistently after acquisitions.

Technology and portfolio priorities

AI drug discovery and autonomous science are emerging as potential share-gain opportunities. Danaher has launched an autonomous laboratory at Abcam and is working with Anthropic and NVIDIA, while diagnostics is being supported by the US rollout of Beckman Coulters DxI 9000 immunoassay platform and continued double-digit growth at Cepheid outside respiratory testing.

Cytiva remains a central biotechnology asset. Management said equipment orders grew at a mid-teens rate in the third quarter and normally convert into revenue within nine to twelve months. Danaher estimates a roughly 1 billion US dollar reshoring opportunity, although the main revenue contribution is expected from 2028 onward.

Execution remains the key test

Montgomery also pointed to high-single-digit growth in China during the third quarter, including stronger performance in biotechnology and life sciences. Abcam has returned to growth for three consecutive quarters after additional commercial investment, while Masimo is being integrated through the Danaher Business System.

For investors, the strategy broadens the recovery case but raises the importance of execution. The next milestones are stronger core growth, visible share gains and evidence that new products, cross-selling and acquisitions are translating into sustainable profitable growth.

Danaher stock remains part of the broader US equity market tracked by the S&P 500.

More news and analyses on Danaher stock